• Psych avatar Psych @psych

'Given the significant morbidity rate associated...novel approaches to treat Alzheimer’s-type cognitive impairment are urgently needed.' Biomind has entered Phase II trials with a 5-MeO-DMT analogue. CEO Alejandro Antalich spoke with @HIGH_TIMES_Mag: https://t.co/dqG1kByN8C

hometechnologypsych

Researchers Studying Psychedelic Drug as Treatment for Alzheimer's Disease | High Times

hightimes.com
Sep 22, 2022
A Toronto-based biotech company is studying a psychedelic drug based on DMT as a treatment for Alzheimer’s disease with a Phase ll clinical trial in Argentina.

Also In Psych

Also In Technology

A Toronto-based biotech company is studying a psychedelic drug based on DMT as a treatment for Alzheimer’s disease with a Phase ll clinical trial in Argentina.